News

Life Sciences

Axsome Shows Positive Phase 2 Data in Major Depressive Disorder

Edward Kim | Equities.com |

AXS-05's novel multimodal mechanism of action is different from all currently marketed antidepressants (Image: Axsome).


NeuBase Therapeutics to Reverse Merge into Ohr Pharmaceutical

Edward Kim | Equities.com |

NeuBase will capture Ohr's Nasdaq listing as it develops therapies for genetic diseases caused by mutant proteins.


Bristol-Myers Squibb to Buy Celgene for $74 Billion

Edward Kim | Equities.com |

CELG shareholders to receive one BMY share + $50 in cash + 1 contingent value right worth potentially $9 for each CELG share


Exicure Shows Positive Early Data in Topical Psoriasis Treatment

Edward Kim | Equities.com |

First demonstrated clinical benefit of company's proprietary spherical nucleic acid (SNA) platform (Image: Exicure)


Biotech IPOs Raise Record Amount of $8.65 Billion in 2018

Edward Kim | Equities.com |

80 deals created $44.8 billion of market value for newly public US biotechs (Image: Genomics Law Report).


Harpoon Therapeutics Files for $75 Million IPO for Cancer Immunotherapy

Edward Kim | Equities.com |

Developing T cell engagers targeting prostate cancer, ovarian cancer, multiple myeloma and small cell lung cancer (Image: Harpoon Therapeutics)


Opiant Pharmaceuticals Licenses Cannabinoid Overdose Therapy from Sanofi

Edward Kim | Equities.com |

Opiant is the developer of Narcan for opioid overdoses


Athenex and MAIA Get Approval for Generic Levothyroxine for Hypothyroidism

Edward Kim | Equities.com |

Hypothyroidism affects 4.6% of the US population aged 12 and older (Image: NIH)


Stemline Gets First FDA Approval for Rare Blood Disease Therapy

Edward Kim | Equities.com |

Elzonris (tagraxofusp) is the first approved treatment for blastic plasmacytoid dendritic dell neoplasm (BPDCN) and first CD123-targeted therapy (Image: Stemline Therapeutics)


Kalytera Shows Positive Phase 2 Data with CBD in Acute Graft vs Host Disease (GvHD)

Edward Kim | Equities.com |

Interim data from first cohort shows no patients have developed severe or life-threatening GvHD (Image: Kalytera Therapeutics)


Emerging Growth

DirectView Holdings Inc

DirectView Holdings Inc designs and installs surveillance systems, digital video recording and services. The company through its subsidiaries operates within two divisions security and surveillance and video conferencing services.

Events

Truth on Trial: Implications for Communicators – Part III

Truth on Trial” is just one of a series of forums put on by the Schar School of Policy & Government, whose panelists are among the most influential legal, communications,…

Learn more